Cord Blood News 12.10 March 19, 2020 | |
| |
TOP STORYCD362+ umbilical cord-human MSCs were as effective as heterogonous MSCs in reducing E. coli-induced acute lung injury, improving oxygenation, decreasing bacterial load, reducing histologic injury, and ameliorating inflammatory marker levels. [Stem Cell Res Ther] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)MSC-microvesicle treatment attenuated bleomycin (BLM)-induced apoptosis and inflammation in BLM-treated L2 cells and ameliorated BLM-induced lung apoptosis, inflammation, and fibrosis in BLM-induced acute lung injury rats. [Stem Cell Res Ther] Full Article A prospectively registered observational study was conducted to assess the significance of allogeneic hematopoietic stem cell transplantation from highly HLA-matched unrelated donors and cord blood on outcomes in adult acute leukemia and myelodysplastic syndrome. [Bone Marrow Transplant] Abstract Perivascular region-MSCs showed the highest mitochondrial activity. Cord lining-MSCs were the least affected by oxygen and glucose deprivation/R condition, suggesting their robust survival in ischemic environment. [Stem Cell Rev Rep] Full Article Magnetic resonance imaging showed that animals treated with human umbilical cord Wharton’s jelly-derived MSCs after moderate intracerebral hemorrhage (ICH) had smaller residual hematoma volumes than vehicle-treated rats, whereas the cell therapy failed to decrease the hematoma volume in animals with a severe ICH. [Stem Cells Dev] Abstract The authors showed that supplementation of dimethyl sulfoxide with ice recrystallization inhibitor (IRI)2 had several beneficial effects. Specifically, higher levels of human platelets were observed in the peripheral blood upon transplant of cord blood units preserved with the IRIs. [Transfusion] Abstract Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News. | |
| |
REVIEWSHematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status Prospective randomized and uncontrolled trials and retrospective case series were reviewed to examine the safety and efficacy of the procedure. [BioDrugs] Abstract Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSCellenkos, Inc. announced that the company has submitted a clinical development proposal to the Biomedical Advanced Research and Development Authority to start a Phase I/II clinical trial with CK0802 for treatment of CoV-ARDS. CK0802, is a novel allogenic cell therapy, consisting of T-regulatory cells derived from clinical-grade umbilical cord blood units, developed from Cellenkos’ proprietary manufacturing platform, that overcomes immune dysfunction by resolving chronic inflammation. [Cellenkos, Inc. (PR Newswire Association LLC)] Press Release Roche announced that the European Commission has approved Venclyxto® in combination with Gazyvaro® for the treatment of adult patients with previously untreated chronic lymphocytic leukemia. [F. Hoffmann-La Roche Ltd] Press Release | |
| |
POLICY NEWSRespirators, Quarantines, and Worst-Case Scenarios: Lab Animal Facilities Grapple with the Pandemic Many universities are currently grappling with the best way to care for the millions of mice, monkeys, and other research animals they care for across the country, in addition to protecting the health of their own employees. [ScienceInsider] Editorial Journals, Peer Reviewers Cope with Surge in COVID-19 Publications Academic journals have already taken steps to accelerate the flow of peer-reviewed information by expediting editorial and peer review for coronavirus-related manuscripts and granting them open-access status upon publication. [The Scientist] Editorial Near-Lockdown in the Bay Area ‘Ratchets Up’ Challenges for Local Biotechs and Labs Seven counties in the San Francisco Bay Area went into near-lockdown — ushering in a new reality for biopharma companies and biomedical labs. The “shelter in place” order offers significant leeway for medical research. [STAT News] Editorial
| |
EVENTSIn light of COVID-19, many conferences are being cancelled or postponed. As such: We are suspending new event postings in our newsletters and on Twitter. Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Group Leader – Pediatric Leukemia (German Cancer Research Center in the Helmholtz Association) Postdoctoral Researcher – Hematologic Malignancies (Northwestern University) Postdoctoral Position – Hematopoietic Stem Cell Biology (Columbia University Medical Center) Postdoctoral Positions – Cancer Research (Moores Cancer Center, UC San Diego) Team Leader – Clonal Evolution in Leukemias (Institute of Cancer Research) Postdoctoral Researcher – Leukemia (Universitätsklinikum Carl Gustav Carus Dresden) Postdoctoral Scientist – Stem Cell Biology (Cancer Research UK Manchester Institute) Research Technician – Graft versus Host Disease (Fred Hutchinson Cancer Research Center) Laboratory Director – Cord Blood Processing (PerkinElmer) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|